Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study
Joseph Mıkhael(Translational Genomics Research Institute), S. Vincent Rajkumar(WinnMed), Kurt R. Oettel(Gundersen Health System), Abraham S. Kanate(HonorHealth), Amylou C. Dueck(Mayo Clinic in Arizona), Sagar Lonial(Emory University), Suzanne R. Hayman, Judith Manola(Dana-Farber Cancer Institute)
Cited by 25
Related Papers
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
|JAMA|2017|2.3k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k